• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·3737.HK
Share

Zhongzhi Pharmaceutical Holdings Limited Stocks

HK$ 0.58Last Updated 27.07.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

HK$ 62.41M

HK$ 0.58
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Zhongzhi Pharmaceutical Holdings Limited, an investment holding firm based in the People's Republic of China, focuses on the entire lifecycle of pharmaceutical products, from research and development to manufacturing and distribution. Its operations are structured across three main divisions: pharmaceutical production, management of its physical retail pharmacy chain, and its online pharmacy platform. The company offers Chinese patent medicines and traditional Chinese decoction pieces, marketed under prominent brands such as Zeus, Liumian, and Caojinghua. In addition to its core pharmaceutical activities, Zhongzhi also produces and sells food products and traditional Chinese herbs, manages properties, and offers detection and testing services. By the end of 2021, the company managed a network of 398 self-owned retail pharmacies. Of these, 361 were approved for medical insurance payments and are situated in Zhongshan, Guangdong Province, operating under the Zeus brand. Established in 1993, the company's headquarters are also located in Zhongshan, PRC. Crystal Talent Investment Group Limited holds a controlling stake in Zhongzhi Pharmaceutical Holdings Limited.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.07.2026 22:30

Oncology drugs helped boost AstraZeneca's profits by 21%. Will the company expand its portfolio?

27.07.2026 22:13

Plata has appointed the former U.S. ambassador to Russia to its board of directors

27.07.2026 21:56

Bank of America announced the temporary closure of its positions in Kazakh government bonds

27.07.2026 21:42

Nvidia has invested in Ilya Sutskever's AI startup. Why is it doing this?

27.07.2026 21:17

Shares of U.S. chipmakers plummeted following the IPO of a Chinese competitor

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026